Eurycoma longifolia Extract Improves Menopausal Quality of Life and Mood with a Strong Safety Profile and Potential for Greater Benefits at Higher Doses

Physta® (standardized Eurycoma longifolia extract) was evaluated in a 12-week randomized, double-blind, placebo-controlled trial involving 138 women aged 40–55 with menopausal symptoms. Participants received either 50 mg, 100 mg, or placebo. The 100 mg dose delivered the most meaningful effects, reducing overall MENQOL scores by 33.9 percent and improving physical and sexual domains by more than 36 percent. Mood disturbance declined by 38.6 percent, greater than placebo, though not statistically significant. Safety remained strong across all arms with no changes in vital signs, biochemical markers or reproductive hormones, confirming hormonal neutrality. The findings suggest Physta® 100 mg may support menopausal quality of life and mood without adverse effects, with potential for stronger outcomes at higher doses or longer duration.

Source : https://www.wjgnet.com/2307-8960/full/v13/i31/109113.htm?appgw_azwaf_jsc=Dm0Ksx6zZC4BOQzMfZrzu77Ie2P8WCYkYTGDppAPAih2iPVBNEJ9N0MtssjPoNHCuqfXkIgBM6BV84VtYg_k8rLne2dnOQx1eLYJQ7KjX7fqNxMKltxSu_f3CA6RYx6Id-1wWoLBxeH-lGysjBgH-s79FbcimwaZOj6KD1OCNEK-Zw8kH3hosph9UX4lf-dwj4QadyezRkVn51qj51mR7IDn1Uupzq3goKVS13zU9LvioDgMJHyU82NWnZuZCyYkR5W4cledBZXmWukpEXQ-D7Wi8swS15tUbHrsyic1IxLQsIfW1sM6KRrS0ghbIKFB3epkSTcJZgcdC7NKZpyv7A